Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200

Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA, targeting $1 billion in revenue by 2028. The DMX-200 licensing deal opens a major market opportunity in FSGS, with positive interim phase 3 data and potential for broader rare renal indications. Financially, Amicus has limited cash but can raise more through its ATM facility, and its approved drugs are generating double-digit sales growth.